Evidence map›Paper›PMID 35538392›Full record

ArticleRheumatology and therapy2022

Associations of Healthcare Utilization and Costs with Increasing Pain and Treatment Intensity Levels in Osteoarthritis Patients: An 18-Year Retrospective Study.

Jove Graham, Tonia Novosat, Haiyan Sun, Brian J Piper, Joseph A Boscarino, Melissa S Kern, Vanessa A Hayduk, Eric A Wright, Craig Beck, Rebecca L Robinson and 3 more

Open access · goldAbstract read
In one paragraph

Article in Rheumatology and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Jove GrahamCenter for Pharmacy Innovation and Outcomes, Geisinger, 100 N Academy Ave, Danville, PA, MC 44-00, USA. jhgraham1@geisinger.edu.ORCID http://orcid.org/0000-0002-7881-8588
Tonia NovosatInterventional Pain, Geisinger, Danville, PA, USA.
Haiyan SunBiostatistics Core, Geisinger, Danville, PA, USA.
Brian J PiperCenter for Pharmacy Innovation and Outcomes, Geisinger, 100 N Academy Ave, Danville, PA, MC 44-00, USA.
Joseph A BoscarinoDepartment of Population Health Sciences, Geisinger, Danville, PA, USA.
Melissa S KernCenter for Pharmacy Innovation and Outcomes, Geisinger, 100 N Academy Ave, Danville, PA, MC 44-00, USA.
Vanessa A HaydukCenter for Pharmacy Innovation and Outcomes, Geisinger, 100 N Academy Ave, Danville, PA, MC 44-00, USA.
Eric A WrightCenter for Pharmacy Innovation and Outcomes, Geisinger, 100 N Academy Ave, Danville, PA, MC 44-00, USA.
Craig BeckPfizer Inc., New York, NY, USA.
Rebecca L RobinsonEli Lilly & Co., Indianapolis, IN, USA.
Edward CaseyPfizer Inc., New York, NY, USA.
Jerry HallEli Lilly & Co., Indianapolis, IN, USA.
Patricia DorlingPfizer Inc., New York, NY, USA.
Geisinger Medical Center · USPfizer (United States) · USEli Lilly (United States) · USGeisinger Health System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionOsteoarthritis (OA) is a complex disease, and prior studies have documented the health and economic burdens of patients with OA compared to those without OA. Our goal was to use two strategies to further stratify OA patients based on both pain and treatment intensity to examine healthcare utilization and costs using electronic records from 2001 to 2018 at a large integrated health system.

methodsAdult patients with ≥1 pain numerical rating scale (NRS) and diagnosis of OA were included. Pain episodes of ≥90 days were defined as mild (0-3), moderate (4-6), or severe (7-10) based on initial NRS. Patients were initially classified as mild and moved to moderate-severe OA if any of eight treatment-based criteria were met. Outpatient visits (OP), emergency department visits (ED), inpatient days, and healthcare costs (both all-cause and OA-specific) were compared among pain levels and OA severity levels as frequencies and per-member-per-year rates, using generalized linear regression models adjusting for age, sex, and body mass index, with contrasts of p < 0.05 considered significant.

resultsWe identified 127,656 patients, 92,576 with pain scores. Moderate and severe pain were associated with significantly higher rates of OA-related utilization and costs, and all-cause ED visits and pharmacy costs. Moderate-severe OA patients had significantly higher OA-related utilization and costs, and all-cause OP, ED and pharmacy costs.

conclusionsPain and treatment intensity were both strongly associated with OA-related utilization but not consistently with all-cause utilization. Our results provide promising evidence of better criteria and approaches for predicting disease burden and costs in the future.

Indexed as

Clinical phenotypingHealth economicsOsteoarthritisPain

Identifiers

PMID35538392
PMCPMC9314498
OpenAlexW4280641258

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.